Aligos Therapeutics, Inc. · NASDAQ:ALGS
Aligos Therapeutics — Investor Presentation (December 2022)
47 slides from Aligos Therapeutics's investor presentation, December 2022
Slide 1: Corporate Presentation December 2022
Lawrence M. Blatt, Ph.D. Chairman, CEO & Co-Founder C Corporate Presentation December 2022
Slide 2: Disclosures
Disclosures This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts contained in this presentation, including statements regarding our future results of operations and f
Slide 3: Aligos Development Portfolio
Aligos Development Portfolio Multiple Milestones/Data Readouts Planned Over 2023 Candidate Indication MOA 2023 Clinical Trial Timelines and Data Readouts Q1 Q2 Q3 Q4 Up to 48 Weeks Dosing in CHB ALG-000184 CAM-E APASL (12 weeks CHB) EASL (≥12 weeks CHB) AASLD (>12 weeks CHB) CHB Single, Multiple Dos
Slide 4: Aligos Discovery Pipeline
Aligos Discovery Pipeline Multiple Candidates Advancing Towards Development Indication MOA Discovery Nonclinical Partnership CAM-A CHB Internal Program Small Molecule PD-L1 CHB Small Molecule Internal Program NASH Oligonucleotide NASH Oligonucleotide Back-Up Protease Inhibitor Coronavirus Internal P
Slide 5: Clinical Strategy for Combination Treatment (e.g., CHB, NASH)
Clinical Strategy for Combination Treatment (e.g., CHB, NASH) MOA #1 Healthy Volunteers Patients Combination Protocol MOA #2 Healthy Volunteers Patients Multiple combinations in patients Pivotal Trial(s) (full treatment course) MOA #3 Healthy Volunteers Patients Safety + PK Safety + PK + PD Safety +
Slide 6: Chronic Hepatitis B
ALIGOS THERAPEUTICS Chronic Hepatitis B
Slide 7: Therapeutic Approaches to CHB Functional Cure
Therapeutic Approaches to CHB Functional Cure Inhibit Viral Replication Lower Antigen Burden Boost Immune Response 6
Slide 8: Inhibiting Viral Replication
Inhibiting Viral Replication • ALG-000184 (CAM-E) 7
Slide 9: ALG-000184 In Vitro Potency vs. Competitor CAM-Es
ALG-000184 In Vitro Potency vs. Competitor CAM-Es HBV DNA Reduction Compound Current Status Cell Type (EC50 nM) 0.63 HepG2.117 Aligos ALG-000184 Phase 1b 0.53 HepG2.2.15 Assembly ABI-H3733 Phase 1b 5 AD38 Enanta EDP-514 Phase 1b 17 HepG2.115 Assembly ABI-4334 Phase 1a 1.2 AD38 Janssen JNJ-6379 Disco
Slide 10: ALG-000184 Phase 1 Study in CHB Subjects
ALG-000184 Phase 1 Study in CHB Subjects Multiple Doses in Currently Not Treated/Treatment Naïve CHB Subjects HBV DNA > 2000 IU/mL, HBeAg- or HBeAg+ Up to 6 cohorts (n=10 per Cohort, n=8 ALG-000184, n=2 Placebo) 28 daily oral doses Endpoints: PK, safety, antiviral activity (e.g., DNA, RNA) Endpoint
Slide 11: ALG-000184-201 Part 3 Cohorts 1-5 Antiviral Activity
ALG-000184-201 Part 3 Cohorts 1-5 Antiviral Activity – HBV DNA and HBV RNA Mean (SEM) Serum HBV DNA and HBV RNA Levels Change from Baseline Through the End of Study HBV DNA* HBV RNA** % <LLOQ % <LLOQ --- 100 --- 100 --- 83 --- 100 --- 75 --- 100 --- 0 --- 0 --- 0 --- 0 HBeAg- CHB subjects: Similar H
Slide 12: ALG-000184 Antiviral Activity vs. Competitor CAM-Es (HBeAg Negative)
ALG-000184 Antiviral Activity vs. Competitor CAM-Es (HBeAg Negative) HBV DNA Drug Name Current Status Dose Mean Decline from BL to EOT % < LLOQ at (Log10 IU/mL) Day 28 ALG-000184 Phase 1 10 mg 3.7 100 200 mg 2.9 N/A EDP-5145,** Phase 1b 800 mg 3.4 N/A Vebicorvir1,2 Discontinued 300 mg 2.5 25 JNJ-637
Slide 13: ALG-000184 HBsAg Reductions Observed in 28-Day Monotherapy
ALG-000184 HBsAg Reductions Observed in 28-Day Monotherapy HBV DNA HBsAg declines with ALG-000184 dosing HBsAg HBsAg returns to baseline after stopping ALG-000184 ALT Day Maximum HBsAg reduction: 0.23 log10 IU/mL 0.35 log10 IU/mL 0.52 log10 IU/mL 0.78 log10 IU/mL 28-day monotherapy at 100 and 300 mg
Slide 14: ALG-000184 Clinical Development Options
ALG-000184 Clinical Development Options Phase 1 Phase 2 TN HBeAg+ CHB 300 mg ALG-000184 x 1-3 years Chronic HBV CAM vs. NA in HBeAg+ CHB subjects DNA Suppression 300 mg in Endpoint: HBV DNA suppression at Wk48 HBeAg+/- x 12-48 weeks TN and VS HBeAg+ and HBeAg- CHB 300 mg ALG-000184 + ALG-125755 (siR
Slide 15: Lowering S-Antigen Burden
Lowering S-Antigen Burden • ALG-125755 (siRNA) 14
Slide 16: Short Interfering Nucleic Acid ALG-125755
Short Interfering Nucleic Acid ALG-125755 Discovery and Advancement of a Differentiated siRNA • siRNAs have demonstrated clinical validation in CHB infected patients • We have designed our siRNA sequences using our proprietary technology and liver targeting conjugation to maximize in vitro and in vi
Slide 17: ALG-125755 Repeat Dosing in the AAV-HBV Mouse Model vs. VIR-2218
ALG-125755 Repeat Dosing in the AAV-HBV Mouse Model vs. VIR-2218 VIR-2218* ALG-125755 Mean Log10 IU/mL HBsAg Reduction Relative to Day 0 Mean Log10 IU/mL HBsAg Reduction Relative to Day 0 ALG-125755 demonstrates a more sustained reduction in HBsAg vs. competitor siRNAs *Data from Anglero-Rodriguez Y
Slide 18: ALG-125755 PXB Humanized Mice Study – No hALT Signal
ALG-125755 PXB Humanized Mice Study – No hALT Signal for ALG-125755 800 Vehicle 600 50 mg/kg ALG-755 %Change hALT 48.3 mg/kg ALN-HBV 400 50 mg/kg Vir-2218 200 0 Doses -200 1 15 29 43 11 15 18 22 25 29 32 36 39 43 46 50 1 4 8 Day Confirmed in the humanized PXB mouse that ALN-HBV is hepatotoxic and VI
Slide 19: ALG-125755-501 Study Timelines
ALG-125755-501 Study Timelines Part 1 SAD HV Parts 2-3 - SAD, MAD in CHB SAD in CHB Cohort 1 Readout (EASL) Nov Dec Jan Feb Mar Apr May Jun Jul Aug Sep 2023 SAD in HV: Part 1 Cohorts 1-4 (20 mg, 60 mg, 100 mg and 200 mg) completed dosing SAD in CHB: Part 2 Cohort 1 currently dosing (50 mg) 18
Slide 20: Clinical Experience with siRNAs
Clinical Experience with siRNAs HBsAg Reduction After 28 Days in CHB Patients Mean HBsAg change from baseline (Log10 IU/mL) Weeks Consistent reductions of ~0.5 log10 IU/mL noted for competitor siRNAs 28 days after a single dose VIR-2218, Yuen et al., AASLD 2022; AB-729, Yuen et al., AASLD 2020; RG63
Slide 21: siRNA and CAM-E Combination Therapy
siRNA and CAM-E Combination Therapy No Antagonism Seen with Assembly CAM-E/Arbutus siRNA Mean Changes in Virologic Parameters On-Treatment Contrary to JNJ REEF-1 siRNA/CAM data, no antagonism seen with Assembly CAM-E/Arbutus siRNA Aligos CHB portfolio (CAM-E, siRNA, PD-L1) has all essential componen
Slide 22: Boosting the Immune Response
Boosting the Immune Response • ALG-093702 (PD-L1 Small Molecule) 21
Slide 23: PD-L1 Inhibitors
PD-L1 Inhibitors • Exhaustion of HBV specific T-cells contributes to the persistence of CHB • Proof of concept in CHB with anti-PD1 antibodies has been established – Multiple clinical studies have demonstrated HBsAg reductions in CHB infected patients • Aligos has discovered several potent series of
Slide 24: ALG-093702 A Potent Small Molecule PD-L1 Inhibitor
ALG-093702 A Potent Small Molecule PD-L1 Inhibitor Nivolumab Durvalumab ALG-093702 PD-1 antibody PD-L1 antibody PD-L1 SMi Human PD-1/PD-L1 Biochemical 0.159 0.025 0.048 Interaction Activity (n=2) (n=2) (n=2) IC50 (nM) Cellular Jurkat PD-1/PD-L1 Blockade 3.3 0.3 5.9 Activity EC50 (nM) (n=2) (n=4) (n=
Slide 25: ALG-093702 Exhibits Liver Targeted Tissue Distribution
ALG-093702 Exhibits Liver Targeted Tissue Distribution ALG-093702 Mouse Tissue Distribution at 6 hours post dose 25000 Liver/plasma ratio = 20 concentration (ng/ml or ng/g) 20000 15000 Oral dose of 52 mg/kg ALG-093701, prodrug 10000 Bioavailability 41% 5000 0 Plasma Liver Colon Kidney Lung Pancreas
Slide 26: ALG-093702 PD-L1 Inhibitor Reactivates the HBV-specific T-Cell Response
ALG-093702 PD-L1 Inhibitor Reactivates the HBV-specific T-Cell Response over HBV piptides alone 40 INF-γ Fold Increase 30 20 10 0 ) ) l) nM nM /m ug 00 00 (5 (1 0 (1 2 2 70 70 ab 93 93 m lu -0 -0 va LG LG ur A A D ALG-093702 reactivates HBV-specific T cells from an HBV-infected patient to a similar
Slide 27: Aligos CHB Strategy Summary
Aligos CHB Strategy Summary • New data from AASLD 2022 confirmed that functional cure › Is achievable with investigational MOAs (e.g., siRNA, ASO), albeit in small numbers › May require one or more HBsAg lowering agents › Will require combination approach, likely including immunomodulators – Arbutus
Slide 28: NASH
NASH ALG-055009, small molecule THR-β agonist 27
Slide 29: ALG-055009 More Potent and Selective In Vitro than MGL-3196 and VK-2809
ALG-055009 More Potent and Selective In Vitro than MGL-3196 and VK-2809 Relative THR-α and THR-β Activity in Cell-Based Assays In vitro, ALG-055009 is 5-47x more potent compared to Resmetirom (MGL-3196) and 2-3x more selective for THR-β than VK-2809* High β selectivity and potency may improve risk-b
Slide 30: ALG-055009 Best In Class Potential vs. 1st Gen THR-β Agonists
ALG-055009 Best In Class Potential vs. 1st Gen THR-β Agonists Parameter VK-2809 MGL-3196 ALG-055009 28 day mouse DIO TC, LDL lowering 28% 28% Up to 44% Percent of patients with ≥30% change 76%-100% 60% High Expected from baseline in MRI-PDFF (Ph2) Efficacy BCRP, OATP substrate ? Yes No (NTCP) AUC/Cm
Slide 31: Study ALG-055009-301 SAD PK, Safety Data
Study ALG-055009-301 SAD PK, Safety Data • Doses evaluated: 0.1, 0.3, 0.9, 2.6, 4.0 mg • PK – Dose proportional PK with low variability, t1/2 = 20-24 hours (supports QD dosing) • Safety: well tolerated – No serious adverse events, premature discontinuations, Grade ≥3 treatment emergent AEs (TEAEs),
Slide 32: Study ALG-055009-301 SAD PD Data
Study ALG-055009-301 SAD PD Data • Expected thyromimetic effects observed: Key SAD Data (% Change From Baseline) generally dose proportional Cohort 1 Cohort 2 Cohort 3 Cohort 4 Cohort 5 Placebo 0.1 mg 0.3 mg 0.9 mg 2.6 mg 4 mg (n = 10) (n = 6) (n = 6) (n = 6) (n = 6) (n = 6) – Increases in Sex Hormo
Slide 33: Study ALG-055009-301 MAD PK, Safety Data
Study ALG-055009-301 MAD PK, Safety Data • Doses evaluated: 0.3, 0.5, 0.6, and 1.0 mg PO QD x 14 days • PK: favorable profile (dose-proportional, low variability, 2x accumulation) • Safety: well tolerated, no clinical evidence of hypo- or hyper-thyroidism – No SAEs, discontinuations – All TEAEs Grad
Slide 34: Study ALG-055009-301 MAD PD – SHBG
Study ALG-055009-301 MAD PD – Sex Hormone Binding Globulin (SHBG) Dosing Period Dose proportional increases in SHBG Charfi et al., AASLD 2022. 33
Slide 35: Study ALG-055009-301 MAD PD – Thyroid Hormones
Study ALG-055009-301 MAD PD – Thyroid Hormones Dosing Period Day Dose responsive reduction in free T4 Up to ~20% declines (while remaining in normal range) for doses ≤0.6 mg Greater declines for 1 mg dose Similar pattern observed for other thyroid hormones Charfi et al., AASLD 2022. 34
Slide 36: Study ALG-055009-301 MAD PD - Lipids
Study ALG-055009-301 MAD PD - Lipids Day Dose responsive reductions in LDL cholesterol Similar pattern observed for Apo-B, Triglycerides Charfi et al., AASLD 2022. 35
Slide 37: ALG-055009 Phase 1 Summary and Next Steps
ALG-055009 Phase 1 Summary and Next Steps • PK demonstrates a favorable profile that is differentiated vs. resmetirom • Safety – well tolerated without clinical safety signals • PD – generally dose proportional – Increases in SHBG – Decreases in thyroid hormones – Decreases in LDL, triglycerides, Ap
Slide 38: Coronavirus
Coronavirus • ALG-097558 (CoV Protease Inhibitor) 37
Slide 39: ALG-097558 Aligos' Potent COVID-19 Protease Inhibitor
ALG-097558 Aligos’ Potent COVID-19 Protease Inhibitor • Despite the availability of prophylactic vaccines, a need for therapeutics still exists – Resistant variants are emerging and may become dominant (e.g., omicron subvariants) – Large segments of global population lack access to, or are opposed t
Slide 40: ALG-097558 Superior Biochemical Potency Against SARS-CoV-2
ALG-097558 Superior Biochemical Potency Against SARS-CoV-2 SARS-CoV-2 3CLpro IC50 (nM)1 Hillslope Ki (nM) PF-07321332 2.92 0.91 2.03 PBI-0451 3.6 1.74 3.4 S-217622 4.0 1.31 2.6 ALG-097558 0.26 1.992 0.074 ALG-097558 Ki is 27-46 fold more potent vs. competitors in the 3CLpro biochemical assay 1The as
Slide 41: ALG-097558 Superior Cell-Based Potency Against SARS-CoV-2 and Variants
ALG-097558 Superior Cell-Based Potency Against SARS-CoV-2 and Variants EC50 (μM) Virus Variant/Cell line Pardes Shionogi Pfizer Aligos PBI-0451 S-217622 PF-07321332 ALG-097558 03021/2020 n.d. n.d. 0.116 0.010 Vero E6+CP B.1.1.7 (alpha) 0.038 0.023 0.099 0.012 A549-ACE2-TMPRSS2 SARS-CoV-2 B.1.617.2 (
Slide 42: ALG-097558 Oral Prophylactic Treatment in the SARS-CoV-2 Hamster Model
ALG-097558 Oral Prophylactic Treatment in the SARS-CoV-2 Hamster Model 7 Dosing (BID) 6 Log10 TCID50/mg lung Ritonavir (RTV), 50 mg/kg Amount of 5 RTV/ALG-097558, 50/25 mg/kg Infectious Virus RTV/ALG-097558, 50/50 mg/kg on Day 4 4 RTV/ALG-097558, 50/100 mg/kg RTV/ALG-097558, 50/150 mg/kg 3 PF-073213
Slide 43: ALG-097558 Oral Therapeutic Treatment in the SARS-CoV-2 Hamster Model
ALG-097558 Oral Therapeutic Treatment in the SARS-CoV-2 Hamster Model ✱✱ ✱✱ 9 ✱✱ Dosing (BID) ✱✱ 8 Ritonavir (RTV), 50 mg/kg ✱✱ 0-hr delay Amount of 7 Log10 TCID50/mg lung RTV/ALG-097558, 50/75 mg/kg Infectious Virus 6 RTV/ALG-097558, 50/25 mg/kg 8-hr delay on Day 4 5 RTV/ALG-097558, 50/75 mg/kg 4 2
Slide 44: ALG-097558 SARS-CoV-2 3CLpro L50F E166A L167F Mutant
ALG-097558 SARS-CoV-2 3CLpro L50F E166A L167F Mutant • ALG-097558 has the least loss of activity against a triple mutant conferring resistance to other SARS-CoV-2 PIs Biochemical VeroE6+CP Compound Name L50F/E166A/L167F L50F/E166A/L167F (fold change versus WT) EC50 [µM] (fold change) PF-07321332 (Pf
Slide 45: ALG-097558 Coronavirus Protease Inhibitor Drug Candidate
ALG-097558 Coronavirus Protease Inhibitor Drug Candidate • Potent pan-coronavirus protease inhibitor drug candidate – Additional candidates from the series advancing as backup compounds • Superior preclinical profile versus PF-07321332 (Pfizer) – 7-27 fold more potent in biochemical and cell-based a
Slide 46: Aligos Therapeutics Summary
Aligos Therapeutics Summary • We are advancing multiple drug candidates with clinically-validated MOAs with the goal of rapidly developing optimized combination regimens – CHB portfolio – complementary MOAs which may increase functional cure rates › CAM-E (ALG-000184) - best in class HBsAg, DNA, RNA
Slide 47: Aligos Therapeutics
ALIGOS THERAPEUTICS
Aligos Therapeutics — Investor Presentation (December 2022) on 6ix